| Trademark Snap Shot Publication Stylesheet (Table presents the data on Publication Approval) |
|||
OVERVIEW |
|||
| SERIAL NUMBER | 77673768 | FILING DATE | 02/19/2009 |
| REG NUMBER | 0000000 | REG DATE | N/A |
| REGISTER | PRINCIPAL | MARK TYPE | TRADEMARK |
| INTL REG # | N/A | INTL REG DATE | N/A |
| TM ATTORNEY | SINGH, TEJBIR |
L.O. ASSIGNED | 106 |
PUB INFORMATION |
|||
| RUN DATE | 02/01/2011 | ||
| PUB DATE | N/A | ||
| STATUS | 680-APPROVED FOR PUBLICATION | ||
| STATUS DATE | 01/31/2011 | ||
| LITERAL MARK ELEMENT | OXFORD BIOMEDICA | ||
| DATE ABANDONED | N/A | DATE CANCELLED | N/A |
| SECTION 2F | NO | SECTION 2F IN PART | NO |
| SECTION 8 | NO | SECTION 8 IN PART | NO |
| SECTION 15 | NO | REPUB 12C | N/A |
| RENEWAL FILED | NO | RENEWAL DATE | N/A |
| DATE AMEND REG | N/A | ||
FILING BASIS |
|||||
| FILED BASIS | CURRENT BASIS | AMENDED BASIS | |||
| 1 (a) | NO | 1 (a) | NO | 1 (a) | NO |
| 1 (b) | YES | 1 (b) | NO | 1 (b) | NO |
| 44D | YES | 44D | NO | 44D | NO |
| 44E | NO | 44E | YES | 44E | NO |
| 66A | NO | 66A | NO | ||
| NO BASIS | NO | NO BASIS | NO | ||
MARK DATA |
|
| STANDARD CHARACTER MARK | YES |
| LITERAL MARK ELEMENT | OXFORD BIOMEDICA |
| MARK DRAWING CODE | 4-STANDARD CHARACTER MARK |
| COLOR DRAWING FLAG | NO |
CURRENT OWNER INFORMATION |
|
| PARTY TYPE | 10-ORIGINAL APPLICANT |
| NAME | Oxford BioMedica plc |
| ADDRESS | The Oxford Science Park Medawar Centre, Robert Robinson Avenue Oxford, OX44GA |
| ENTITY | 11-COMPANY |
| CITIZENSHIP | United Kingdom |
GOODS AND SERVICES |
|
| INTERNATIONAL CLASS | 001 |
| DESCRIPTION TEXT | Chemicals for use in industry and science; enzymes for scientific and research purposes; biochemicals, namely, precursors for in vitro genetic engineering use; polypeptides for in vitro research use, monoclonal antibodies for in vitro scientific or research use; chemicals for use in the purification of proteins for in vitro use; diagnostic reagents for in vitro use in biochemistry, clinical chemistry and microbiology; laboratory chemicals, namely, an antibody reagent used for the detection of antigens in cell and tissue analysis for in vitro diagnostic use; micro-organisms for laboratory and scientific research use, viruses for laboratory and scientific research use, cell cultures for laboratory and scientific research use, plasmids and cultures of micro-organisms for laboratory and scientific research use, nucleic acid sequences for laboratory and scientific research use, cloning vehicles in the nature of plasmids, microbes and chemical reagents for DNA cloning for laboratory and scientific research use, chemicals for laboratory, scientific and biotechnology research and development and recombinant nucleic acid variations thereof for laboratory and scientific research use, namely, in vitro and in vivo use |
| INTERNATIONAL CLASS | 005 |
| DESCRIPTION TEXT | Gene therapy and prophylactic products, namely, gene delivery pharmaceuticals; small molecules, vaccines, biologics, enzymes and enzyme preparations all for medical treatment purposes; pharmaceuticals for medical purposes for the delivery of genes to cells; viral, retroviral and non-viral vectors, all for medical purposes in gene therapy; pharmaceutical and biochemical preparations for the treatment or prevention of cancer, infectious disease, fungal diseases, diseases caused by parasites, namely, hookworms, pinworms, roundworms, tapeworms, flukes, giardia, entameoba, cryptosporidium, toxoplasmosis, sleeping sickness, trichuriasis, isosporiasis, malaria, parasitic skin disease and leishmaniasis, eye diseases, diseases of the central and peripheral nervous systems, namely, ataxia, dementia, epilepsy, Alzheimer's, cerebral palsy, stroke, motor neuron disease, Parkinson's disease, spinal injury, avulsion injury and peripheral neuropathies, cardiovascular disease, diseases affecting the immune system, namely, cancer, Crohn's disease, AIDS, HIV, lupus, celiac disease, diabetes, Grave's disease, Guillain-Barré syndrome, Addison's disease, Hashimoto's disease, myasthenia gravis, narcolepsy, pernicious anaemia, rheumatoid arthritis, psoriasis, ulcerative colitis, immunodeficiency and inflammatory diseases, inherited diseases, namely, genetic disorders, hemophilia, cystic fibrosis and Huntingdon's, single gene disorders, bone and blood diseases and reproductive system disorders; pharmaceutical and biochemical preparations for contraceptive purposes; pre-filled vials for medical purposes and for pharmaceutical and biochemical preparations, for use in gene therapy and for the treatment or prevention of cancer, infectious disease, fungal diseases, diseases caused by parasites, namely, hookworms, pinworms, roundworms, tapeworms, flukes, giardia, entameoba, cryptosporidium, toxoplasmosis, sleeping sickness, trichuriasis, isosporiasis, malaria, parasitic skin disease and leishmaniasis, eye diseases, diseases of the central and peripheral nervous systems, namely, ataxia, dementia, epilepsy, Alzheimer's, cerebral palsy, stroke, motor neuron disease, Parkinson's disease, spinal injury, avulsion injury and peripheral neuropathies, cardiovascular disease, diseases affecting the immune system, namely, cancer, Crohn's disease, AIDS, HIV, lupus, celiac disease, diabetes, Grave's disease, Guillain-Barré syndrome, Addison's disease, Hashimoto's disease, myasthenia gravis, narcolepsy, pernicious anaemia, rheumatoid arthritis, psoriasis, ulcerative colitis, immunodeficiency and inflammatory diseases, inherited diseases, namely, genetic disorders, hemophilia, cystic fibrosis and Huntingdon's, single gene disorders, bone and blood diseases and reproductive system disorders |
| INTERNATIONAL CLASS | 010 |
| DESCRIPTION TEXT | Instruments and apparatus for the administration of pharmaceutical, gene therapy and/or vaccine preparations and substances, namely, medical syringes and injectors for medical purposes |
| INTERNATIONAL CLASS | 042 |
| DESCRIPTION TEXT | Scientific, pharmaceutical and medical research and development; genetic engineering services, biotechnology services, namely, research and development for new products in the field of biotechnology, advisory services relating to gene therapy products and clinical trials, conducting clinical trials |
| INTERNATIONAL CLASS | 044 |
| DESCRIPTION TEXT | Medical services; advisory services relating to vaccination regimes; advisory services relating to the treatment, relief and/or prevention of cancer, infectious diseases, fungal diseases, diseases caused by parasites, namely, hookworms, pinworms, roundworms, tapeworms, flukes, giardia, entameoba, cryptosporidium, toxoplasmosis, sleeping sickness, trichuriasis, isosporiasis, malaria, parasitic skin disease and leishmaniasis, eye diseases, diseases of the central and peripheral nervous systems, namely, ataxia, dementia, epilepsy, Alzheimer's, cerebral palsy, stroke, motor neuron disease, Parkinson's disease, spinal injury, avulsion injury and peripheral neuropathies, cardiovascular disease, diseases affecting the immune system, namely, cancer, Crohn's disease, AIDS, HIV, lupus, celiac disease, diabetes, Grave's disease, Guillain-Barré syndrome, Addison's disease, Hashimoto's disease, myasthenia gravis, narcolepsy, pernicious anaemia, rheumatoid arthritis, psoriasis, ulcerative colitis, immunodeficiency and inflammatory diseases, inherited diseases, namely, genetic disorders, hemophilia, cystic fibrosis and Huntingdon's, single gene disorders, bone and blood diseases and reproductive system disorders and contraceptives |
GOODS AND SERVICES CLASSIFICATION |
|||||||
| INTERNATIONAL CLASS | 001 | FIRST USE DATE | NONE | FIRST USE IN COMMERCE DATE | NONE | CLASS STATUS | 6-ACTIVE |
| INTERNATIONAL CLASS | 005 | FIRST USE DATE | NONE | FIRST USE IN COMMERCE DATE | NONE | CLASS STATUS | 6-ACTIVE |
| INTERNATIONAL CLASS | 010 | FIRST USE DATE | NONE | FIRST USE IN COMMERCE DATE | NONE | CLASS STATUS | 6-ACTIVE |
| INTERNATIONAL CLASS | 042 | FIRST USE DATE | NONE | FIRST USE IN COMMERCE DATE | NONE | CLASS STATUS | 6-ACTIVE |
| INTERNATIONAL CLASS | 044 | FIRST USE DATE | NONE | FIRST USE IN COMMERCE DATE | NONE | CLASS STATUS | 6-ACTIVE |
MISCELLANEOUS INFORMATION/STATEMENTS |
|
| CHANGE IN REGISTRATION | NO |
| DISCLAIMER W/PREDETER TXT | "OXFORD" |
| PSEUDO MARK | OXFORD BIO MEDICAL |
FOREIGN INFORMATION |
|
| PRIORITY CLAIMED | SEC. 44(D) ON Office for Harmonization in the Internal Market (Trade Marks and Designs) (OHIM) |
| APPLICATION NO. | 008110744 |
| APPLICATION FILING DATE | 02/18/2009 |
| FOREIGN REG NO. | 008110744 |
| FOREIGN REG DATE | 12/11/2009 |
| FOREIGN RNWL NUM | N/A |
| DATE OF FOREIGN RNWL | N/A |
| FOREIGN EXPIRATION | 02/18/2019 |
| FOREIGN RNWL EXPIRATION | N/A |
PROSECUTION HISTORY |
||||
| DATE | ENT CD | ENT TYPE | DESCRIPTION | ENT NUM |
| 01/31/2011 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER | 029 |
| 01/31/2011 | XAEC | I | EXAMINER'S AMENDMENT ENTERED | 028 |
| 01/31/2011 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | 027 |
| 01/31/2011 | GNEA | O | EXAMINERS AMENDMENT E-MAILED | 026 |
| 01/31/2011 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN | 025 |
| 01/06/2011 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | 024 |
| 01/06/2011 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | 023 |
| 01/06/2011 | ALIE | A | ASSIGNED TO LIE | 022 |
| 12/09/2010 | ERSI | I | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | 021 |
| 06/14/2010 | GNS2 | O | NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED | 020 |
| 06/14/2010 | GNSI | S | INQUIRY TO SUSPENSION E-MAILED | 019 |
| 06/14/2010 | CNSI | R | SUSPENSION INQUIRY WRITTEN | 018 |
| 12/11/2009 | GNS3 | O | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | 017 |
| 12/11/2009 | GNSL | S | LETTER OF SUSPENSION E-MAILED | 016 |
| 12/11/2009 | CNSL | R | SUSPENSION LETTER WRITTEN | 015 |
| 12/01/2009 | GNS3 | O | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | 014 |
| 12/01/2009 | GNSL | S | LETTER OF SUSPENSION E-MAILED | 013 |
| 12/01/2009 | CNSL | R | SUSPENSION LETTER WRITTEN | 012 |
| 11/20/2009 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | 011 |
| 11/20/2009 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | 010 |
| 11/20/2009 | ALIE | A | ASSIGNED TO LIE | 009 |
| 11/09/2009 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | 008 |
| 05/11/2009 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | 007 |
| 05/11/2009 | GNRT | F | NON-FINAL ACTION E-MAILED | 006 |
| 05/11/2009 | CNRT | R | NON-FINAL ACTION WRITTEN | 005 |
| 05/11/2009 | DOCK | D | ASSIGNED TO EXAMINER | 004 |
| 02/24/2009 | MPMK | O | NOTICE OF PSEUDO MARK MAILED | 003 |
| 02/23/2009 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM | 002 |
| 02/23/2009 | NWAP | I | NEW APPLICATION ENTERED IN TRAM | 001 |
CURRENT CORRESPONDENCE INFORMATION |
|
| ATTORNEY | Howard N. Aronson |
| CORRESPONDENCE ADDRESS | HOWARD N. ARONSON LACKENBACH SIEGEL LLP 1 CHASE RD SCARSDALE, NY 10583-4156 |
| DOMESTIC REPRESENTATIVE | Howard N. Aronson |